FMP
Inhibrx Biosciences, Inc.
INBX
NASDAQ
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
14.1 USD
-0.05 (-0.355%)
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2.76B
1.76B
1.57B
1.39B
1.38B
1.18B
1B
853.43M
727.07M
619.42M
-
-36.34
-10.71
-11.56
-0.61
-14.81
-14.81
-14.81
-14.81
134.53M
19.82M
-133.01M
76.93M
62.37M
17.84M
15.2M
12.95M
11.03M
9.4M
4.87
1.13
-8.47
5.54
4.52
1.52
1.52
1.52
1.52
-33.71M
-36.27M
-27.65M
-23.55M
-23.6M
-19.87M
-16.93M
-14.42M
-12.29M
-10.47M
-1.22
-2.06
-1.76
-1.7
-1.71
-1.69
-1.69
-1.69
-1.69
100.82M
-16.45M
-160.66M
53.38M
38.77M
-2.03M
-1.73M
-1.47M
-1.26M
-1.07M
1.91
32.56M
10.51
10.51
366.79M
62.19M
428.98M
85.5
14.5
9.25
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2.76B
1.76B
1.57B
1.39B
1.38B
1.18B
1B
853.43M
727.07M
619.42M
134.53M
19.82M
-133.01M
76.93M
62.37M
17.84M
15.2M
12.95M
11.03M
9.4M
-33.71M
-36.27M
-27.65M
-23.55M
-23.6M
-19.87M
-16.93M
-14.42M
-12.29M
-10.47M
100.82M
-16.45M
-160.66M
53.38M
38.77M
-2.03M
-1.73M
-1.47M
-1.26M
-1.07M
9.25
9.25
9.25
9.25
9.25
-1.86M
-1.45M
-1.13M
-881.81k
-687.64k
-6.01M
9.25
-1.09M
-15.06M
-9.67M
-15.68M
325.52M
-341.2M
32.56M
-10.48
-10.48 1.182%